The recommended path
Three lines, entered in the order their regulatory lanes allow, and the first carries most of what the entry is worth.
Three lines, entered in the order their regulatory lanes allow.
Line A, private-label printed electrodes. Electrosurgical return electrodes, ECG and defibrillation pads, ostomy leakage-sensor layers. These use silver/silver chloride and carbon on film, which MERIDIAN already holds, on roll-to-roll, which is its cost advantage. Sold to companies that already hold the clearance, so no design-in. First revenue 2028, reaching $117.1M by 2032 at 22% gross margin, which is 30.9% of the commodity pool as sized at 2029. That share is high because the pool is small once it is priced at what a contract manufacturer is paid; measured against the pool grown to 2032 it is nearer a quarter.
That revenue is built from units rather than asserted, because a figure in this category implies a volume that has to fit both the market and the plant:
| Product | Share of its reachable pool | Revenue 2032 | Units implied |
|---|---|---|---|
| ECG monitoring electrodes | 30% | $47.8M | 797M |
| Electrosurgical return electrodes | 32% | $46.4M | 77M |
| Ostomy sensor layers | 30% | $15.5M | 13M |
| Defibrillation and pacing pads | 32% | $7.4M | 4M |
| Total | $117.1M | 891M |
Each product is sized as a share of its own reachable pool rather than by setting a unit count, so that a change in any merchant share flows through to revenue. That matters because the merchant shares are the least certain figures here: if the ECG share is half what is assumed, this line loses about $24M of 2032 revenue, and the sizing has to show that rather than absorb it.
The unit count is the consequence worth looking at. 891 million printed electrodes a year, most of them ECG electrodes at six cents, needs about ten roll-to-roll lines at a conservative web speed. That is a large industrial commitment for $117M of revenue at 22% gross margin, and it is the clearest statement of what this tier is: enormous volume for very little money.
At a conservative roll-to-roll web speed of 15 meters a minute, 20 hours a day across 200 production days, on a 300mm web carrying 24 electrodes per meter, one line produces about 86 million units a year. The private-label line at full volume needs about ten. That is a real capital and capacity commitment and it is what the capacity discussion later in this analysis returns to.
Line B, single-use electronic modules. On-body injectors, point-of-care cartridges, wearable cardiac patches. The enabling capability is low-temperature bonding of a die onto PET, which is what lets silicon sit on a cheap web. Buyers are pharmaceutical and diagnostics companies without electronics plants, and frequently the device platform companies that serve them, which makes MERIDIAN a second-tier supplier on part of this line. First revenue 2030, except for the CGM module development already in flight, which began its technical qualification before this decision and is therefore ahead of the lane.
Line B is sized against the contestable pool rather than the merchant pool, because the merchant pool is mostly already placed with Phillips-Medisize, Nolato and their peers. At 55% of the $50.8M contestable in this horizon, it reaches $27.9M by 2032 at 28% gross margin. That 55% is itself aggressive for a new entrant, and at 40% the line is $20.3M. The line is small because the cartridge opportunity, which would be the largest part of it, could not be sized.
Line C, interventional and implantable thin film. Electrophysiology mapping arrays, thin-film sEEG grids, neurostimulation electrodes, liquid crystal polymer packaging. Liquid crystal polymer is the most differentiated material MERIDIAN holds and the least exploited: its water permeability is comparable to glass and it can be monolithically encapsulated and laser-welded. Of the implant categories it could serve, two are sized here: neurostimulation electrodes at $22.0M of reachable pool and electrophysiology mapping arrays at $39.9M, together $61.9M. Cochlear implants were assessed and not carried, and the retinal category has no commercial market left. So the platform argument is real on capability and narrow on attainability: one customer group, not three. First revenue 2030 for the Class II products, 2032 for implantables. Reaching $20M by 2032 at 48% gross margin.
The revenue that follows:
| Year | Line A | Line B | Line C | Total |
|---|---|---|---|---|
| 2027 | 0 | 0 | 0 | $0M |
| 2028 | 3.7 | 0 | 0 | $3.7M |
| 2029 | 30.1 | 4.0 | 0 | $34.1M |
| 2030 | 54.1 | 7.3 | 4.0 | $65.4M |
| 2031 | 87.0 | 16.7 | 10.9 | $114.6M |
| 2032 | 117.1 | 27.9 | 19.8 | $164.8M |
Against the $350M bar set for 2029, this reaches 9.7%, and the bar is not reached inside the six-year horizon at all.
Any statement about when it would be reached is an extrapolation past the model, so both ends of the defensible range are given rather than one. The ramp's 2029-to-2032 compound growth is 69.1%, which is a ramp rate and cannot continue. Its final-year growth is 43.8%; carried forward, $164.8M passes $350M during 2035, six years after the target date. At the 8% blended growth of the underlying markets, which is what a mature business in these segments would sustain, it does not pass $350M until the early 2040s. Neither figure is a forecast; both say the same thing, which is that this ramp does not reach the bar on any horizon the decision cares about. The truth is between them, and the choice does not change the decision, which is why both are stated rather than one being selected.
BCI and CGM are deliberately not lines. CGM continues as a development relationship inside Line B. BCI continues as research with no revenue attached.
Where the rest of the shortlist went
Twenty-one candidates were carried into the case. Not all of them survived into a revenue line, and a candidate that disappears without explanation is a candidate nobody decided about.
- Disposition
- Inside Line A
- Disposition
- Inside Line B
- Disposition
- Inside Line C
- Disposition
- Continues as development inside Line B, not sized as a line
- Disposition
- Research only
- Disposition
- Not carried. It has the shortest path to revenue of anything found, no reimbursement gate and high margin, and it was the strongest candidate on speed. It is excluded because the aesthetics channel sells to clinic chains and distributors rather than to device manufacturers, which is a third commercial motion on top of the two the plan already funds. It should be revisited if the test program reopens the case, where its short cycle would matter more
- Disposition
- Not carried as separate lines. Each is a design-in module sale to a device OEM, so they are the same motion as Line B and would be pursued as Line B programs rather than as their own business
- Disposition
- Not carried. The same roll-to-roll process as Line A, but sold into diagnostics brands where the value sits in the assay chemistry MERIDIAN does not own
- Disposition
- Not a separate line. It is the description of what Lines A to C amount to, and treating it as an option separate from them would double-count
The one exclusion worth arguing with is RF microneedling. It is the fastest route to revenue in the whole candidate set and the plan does not take it. The judgment is that a third commercial motion, entered at the same time as two others, is what turns a focused entry into a diffuse one. That judgment would change if the test program reopens the case and module design-ins look slow.
The route into CGM that does exist
The merchant share in CGM is put at 5% because every scaled maker builds its own sensor. That is a statement about incumbents, and it does not bind new entrants.
Sibionics and Yuwell together took 12% of the Chinese CGM market within a year by pricing 30% to 40% below Abbott, and Chinese manufacturers are now entering Europe and the United States. A challenger without a sensor plant applies the same make-or-buy rule as Abbott and reaches the opposite answer, because it has no in-house capacity to protect and no time to build one.
The counter-argument is that these particular challengers are vertically integrated by design, since their whole proposition is cost. That is why the merchant share is 5% rather than higher, and why this is a first-stage test rather than a line in the plan. Approaching three CGM challengers on second-source supply costs almost nothing and settles whether the figure is 5% or materially better.